A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma.
Trabectedin, a new antitumor compound originally derived from a marine tunicate, is clinically effective in soft tissue sarcoma. The drug has shown a high selectivity for myxoid liposarcoma, characterized by the translocation t(12;16)(q13; p11) leading to the expression of FUS-CHOP fusion gene. Trab...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3327679?pdf=render |
id |
doaj-df7fcf4c07b94e80b65b54dee8986e34 |
---|---|
record_format |
Article |
spelling |
doaj-df7fcf4c07b94e80b65b54dee8986e342020-11-25T02:40:00ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0174e3542310.1371/journal.pone.0035423A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma.Sarah UboldiEnrica CaluraLuca BeltrameIlaria Fuso NeriniSergio MarchiniDuccio CavalieriEugenio ErbaGiovanna ChiorinoPaola OstanoDaniela D'AngeloMaurizio D'IncalciChiara RomualdiTrabectedin, a new antitumor compound originally derived from a marine tunicate, is clinically effective in soft tissue sarcoma. The drug has shown a high selectivity for myxoid liposarcoma, characterized by the translocation t(12;16)(q13; p11) leading to the expression of FUS-CHOP fusion gene. Trabectedin appears to act interfering with mechanisms of transcription regulation. In particular, the transactivating activity of FUS-CHOP was found to be impaired by trabectedin treatment. Even after prolonged response resistance occurs and thus it is important to elucidate the mechanisms of resistance to trabectedin. To this end we developed and characterized a myxoid liposarcoma cell line resistant to trabectedin (402-91/ET), obtained by exposing the parental 402-91 cell line to stepwise increases in drug concentration. The aim of this study was to compare mRNAs, miRNAs and proteins profiles of 402-91 and 402-91/ET cells through a systems biology approach. We identified 3,083 genes, 47 miRNAs and 336 proteins differentially expressed between 402-91 and 402-91/ET cell lines. Interestingly three miRNAs among those differentially expressed, miR-130a, miR-21 and miR-7, harbored CHOP binding sites in their promoter region. We used computational approaches to integrate the three regulatory layers and to generate a molecular map describing the altered circuits in sensitive and resistant cell lines. By combining transcriptomic and proteomic data, we reconstructed two different networks, i.e. apoptosis and cell cycle regulation, that could play a key role in modulating trabectedin resistance. This approach highlights the central role of genes such as CCDN1, RB1, E2F4, TNF, CDKN1C and ABL1 in both pre- and post-transcriptional regulatory network. The validation of these results in in vivo models might be clinically relevant to stratify myxoid liposarcoma patients with different sensitivity to trabectedin treatment.http://europepmc.org/articles/PMC3327679?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sarah Uboldi Enrica Calura Luca Beltrame Ilaria Fuso Nerini Sergio Marchini Duccio Cavalieri Eugenio Erba Giovanna Chiorino Paola Ostano Daniela D'Angelo Maurizio D'Incalci Chiara Romualdi |
spellingShingle |
Sarah Uboldi Enrica Calura Luca Beltrame Ilaria Fuso Nerini Sergio Marchini Duccio Cavalieri Eugenio Erba Giovanna Chiorino Paola Ostano Daniela D'Angelo Maurizio D'Incalci Chiara Romualdi A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma. PLoS ONE |
author_facet |
Sarah Uboldi Enrica Calura Luca Beltrame Ilaria Fuso Nerini Sergio Marchini Duccio Cavalieri Eugenio Erba Giovanna Chiorino Paola Ostano Daniela D'Angelo Maurizio D'Incalci Chiara Romualdi |
author_sort |
Sarah Uboldi |
title |
A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma. |
title_short |
A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma. |
title_full |
A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma. |
title_fullStr |
A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma. |
title_full_unstemmed |
A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma. |
title_sort |
systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2012-01-01 |
description |
Trabectedin, a new antitumor compound originally derived from a marine tunicate, is clinically effective in soft tissue sarcoma. The drug has shown a high selectivity for myxoid liposarcoma, characterized by the translocation t(12;16)(q13; p11) leading to the expression of FUS-CHOP fusion gene. Trabectedin appears to act interfering with mechanisms of transcription regulation. In particular, the transactivating activity of FUS-CHOP was found to be impaired by trabectedin treatment. Even after prolonged response resistance occurs and thus it is important to elucidate the mechanisms of resistance to trabectedin. To this end we developed and characterized a myxoid liposarcoma cell line resistant to trabectedin (402-91/ET), obtained by exposing the parental 402-91 cell line to stepwise increases in drug concentration. The aim of this study was to compare mRNAs, miRNAs and proteins profiles of 402-91 and 402-91/ET cells through a systems biology approach. We identified 3,083 genes, 47 miRNAs and 336 proteins differentially expressed between 402-91 and 402-91/ET cell lines. Interestingly three miRNAs among those differentially expressed, miR-130a, miR-21 and miR-7, harbored CHOP binding sites in their promoter region. We used computational approaches to integrate the three regulatory layers and to generate a molecular map describing the altered circuits in sensitive and resistant cell lines. By combining transcriptomic and proteomic data, we reconstructed two different networks, i.e. apoptosis and cell cycle regulation, that could play a key role in modulating trabectedin resistance. This approach highlights the central role of genes such as CCDN1, RB1, E2F4, TNF, CDKN1C and ABL1 in both pre- and post-transcriptional regulatory network. The validation of these results in in vivo models might be clinically relevant to stratify myxoid liposarcoma patients with different sensitivity to trabectedin treatment. |
url |
http://europepmc.org/articles/PMC3327679?pdf=render |
work_keys_str_mv |
AT sarahuboldi asystemsbiologyapproachtocharacterizetheregulatorynetworksleadingtotrabectedinresistanceinaninvitromodelofmyxoidliposarcoma AT enricacalura asystemsbiologyapproachtocharacterizetheregulatorynetworksleadingtotrabectedinresistanceinaninvitromodelofmyxoidliposarcoma AT lucabeltrame asystemsbiologyapproachtocharacterizetheregulatorynetworksleadingtotrabectedinresistanceinaninvitromodelofmyxoidliposarcoma AT ilariafusonerini asystemsbiologyapproachtocharacterizetheregulatorynetworksleadingtotrabectedinresistanceinaninvitromodelofmyxoidliposarcoma AT sergiomarchini asystemsbiologyapproachtocharacterizetheregulatorynetworksleadingtotrabectedinresistanceinaninvitromodelofmyxoidliposarcoma AT ducciocavalieri asystemsbiologyapproachtocharacterizetheregulatorynetworksleadingtotrabectedinresistanceinaninvitromodelofmyxoidliposarcoma AT eugenioerba asystemsbiologyapproachtocharacterizetheregulatorynetworksleadingtotrabectedinresistanceinaninvitromodelofmyxoidliposarcoma AT giovannachiorino asystemsbiologyapproachtocharacterizetheregulatorynetworksleadingtotrabectedinresistanceinaninvitromodelofmyxoidliposarcoma AT paolaostano asystemsbiologyapproachtocharacterizetheregulatorynetworksleadingtotrabectedinresistanceinaninvitromodelofmyxoidliposarcoma AT danieladangelo asystemsbiologyapproachtocharacterizetheregulatorynetworksleadingtotrabectedinresistanceinaninvitromodelofmyxoidliposarcoma AT mauriziodincalci asystemsbiologyapproachtocharacterizetheregulatorynetworksleadingtotrabectedinresistanceinaninvitromodelofmyxoidliposarcoma AT chiararomualdi asystemsbiologyapproachtocharacterizetheregulatorynetworksleadingtotrabectedinresistanceinaninvitromodelofmyxoidliposarcoma AT sarahuboldi systemsbiologyapproachtocharacterizetheregulatorynetworksleadingtotrabectedinresistanceinaninvitromodelofmyxoidliposarcoma AT enricacalura systemsbiologyapproachtocharacterizetheregulatorynetworksleadingtotrabectedinresistanceinaninvitromodelofmyxoidliposarcoma AT lucabeltrame systemsbiologyapproachtocharacterizetheregulatorynetworksleadingtotrabectedinresistanceinaninvitromodelofmyxoidliposarcoma AT ilariafusonerini systemsbiologyapproachtocharacterizetheregulatorynetworksleadingtotrabectedinresistanceinaninvitromodelofmyxoidliposarcoma AT sergiomarchini systemsbiologyapproachtocharacterizetheregulatorynetworksleadingtotrabectedinresistanceinaninvitromodelofmyxoidliposarcoma AT ducciocavalieri systemsbiologyapproachtocharacterizetheregulatorynetworksleadingtotrabectedinresistanceinaninvitromodelofmyxoidliposarcoma AT eugenioerba systemsbiologyapproachtocharacterizetheregulatorynetworksleadingtotrabectedinresistanceinaninvitromodelofmyxoidliposarcoma AT giovannachiorino systemsbiologyapproachtocharacterizetheregulatorynetworksleadingtotrabectedinresistanceinaninvitromodelofmyxoidliposarcoma AT paolaostano systemsbiologyapproachtocharacterizetheregulatorynetworksleadingtotrabectedinresistanceinaninvitromodelofmyxoidliposarcoma AT danieladangelo systemsbiologyapproachtocharacterizetheregulatorynetworksleadingtotrabectedinresistanceinaninvitromodelofmyxoidliposarcoma AT mauriziodincalci systemsbiologyapproachtocharacterizetheregulatorynetworksleadingtotrabectedinresistanceinaninvitromodelofmyxoidliposarcoma AT chiararomualdi systemsbiologyapproachtocharacterizetheregulatorynetworksleadingtotrabectedinresistanceinaninvitromodelofmyxoidliposarcoma |
_version_ |
1724783613286809600 |